ライフサイエンスコーパス: rectal examination

1 ble resistance and pain/blood during digital rectal examination.

2 ere was still no palpable disease on digital rectal examination.

3 and palpable stools in the rectum at digital rectal examination.

4 for prostate-specific antigen and a digital rectal examination.

5 were 85% for PSA testing and 86% for digital rectal examination.

6 esting and ranged from 41 to 46% for digital rectal examination.

7 d an annual measurement of PSA and a digital rectal examination.

8 ne screening or of stool obtained by digital rectal examination.

9 ite normal PSA levels and results of digital rectal examination.

10 udinal prostate-specific antigen and digital rectal examination.

11 periodic PSA testing (all cohorts), digital rectal examination (14 cohorts), and rebiopsy (14 cohort

12 for men with no cancer suspected on digital rectal examination, a PSA level of 4.0 to 5.0 ng/mL is a

13 years of age or older with a normal digital rectal examination and a prostate-specific antigen (PSA)

14 esponse to AD as assessed by monthly digital rectal examination and prostate-specific antigen (PSA).

15 ly detection of prostate cancer with digital rectal examination and prostate-specific antigen have co

16 eptable operating characteristics of digital rectal examination and prostate-specific antigen, a stag

17 er-screening programs and had normal digital rectal examination and PSA levels (<4 ng/ml).

18 These data suggest that (1) digital rectal examination and PSA levels are insensitive indica

19 ositive predictive value of combined digital rectal examination and PSA measurement has been defined,

20 set of assumptions is used, one-time digital rectal examination and PSA measurement may increase aver

21 ost-effectiveness model for one-time digital rectal examination and PSA measurement was constructed t

22 Likelihood ratios for digital rectal examination and PSA measurement were estimated fr

23 Digital rectal examination and urinalysis should be performed.

24 pecific antigen level or an abnormal digital rectal examination and was offered to all men at the tri

25 bnormal prostate-specific antigen or digital rectal examination) and 669 detected not for cause (with

26 state-specific antigen measurements, digital rectal examinations, and biopsies, with treatment at dis

27 e prostate-specific antigen testing, digital rectal examinations, and serial prostate biopsies.

28 ate-specific antigen measurement and digital rectal examination at 3-month intervals).

29 However, digital rectal examination detects cancer that would otherwise b

30 n two steps, initially using PSA and digital rectal examination (DRE) alone and subsequently using th

31 tate needle biopsy due to suspicious digital rectal examination (DRE) findings and/or PSA levels (lim

32 ombined-modality therapy (CMT) using digital rectal examination (DRE) has been proposed as a means of

33 ence PSA doubling time, and positive digital rectal examination (DRE) of the prostatic fossa were all

34 dy included 118 patients with normal digital rectal examination (DRE) results but elevated prostate-s

35 ymptomatic, but 33 had heme-positive digital rectal examination (DRE) results or hematochezia at rout

36 We defined serendipity in digital rectal examination (DRE) screening as the discovery of a

37 igen (PSA) concentration, PSA slope, digital rectal examination, dysplastic glands or prostatitis on

38 were followed up with PSA assays and digital rectal examinations every 3 months for the first year, s

39 mission for lower gastrointestinal bleeding, rectal examination findings, heart rate, systolic blood

40 peated this interpretation with knowledge of rectal examination findings, sextant biopsy results, and

41 prostate-specific antigen levels and digital rectal examination findings, were correlated with biopsy

42 serum prostate-specific antigen and digital rectal examination, followed by transrectal ultrasound-g

43 d annual PSA testing for 6 years and digital rectal examination for 4 years.

44 re sensitive than sextant biopsy and digital rectal examination for sextant localization of cancer re

45 4.0 ng per milliliter or an abnormal digital rectal examination, had a final PSA determination, and u

46 On digital rectal examination, his prostate was moderately enlarged

47 ce/ethnicity, prior biopsy, PSA, and digital rectal examination) improved the stratification of cance

48 ore sensitive but less specific than digital rectal examination in the detection of local recurrence.

49 y and specificity of sextant biopsy, digital rectal examination, MR imaging, and MR spectroscopy were

50 Sextant biopsy, digital rectal examination, MR imaging, MR spectroscopy, and sal

51 ntigen (PSA) of 4.0 ng/mL or less, a digital rectal examination not suspicious for prostate cancer, a

52 igen level of 4 ng/mL or less, and a digital rectal examination not suspicious for prostate cancer.

53 The tumor was palpable on digital rectal examination on the anterior wall of rectum.

54 e-specific-antigen (PSA) testing and digital rectal examination on the rate of death from prostate ca

55 opsy because of abnormal findings on digital rectal examination or elevated PSA (> or = 4 ng/ml) part

56 levels, usually in combination with digital rectal examination or transrectal prostatic ultrasonogra

57 preceding prostate-specific antigen/digital rectal examination prompt (yes/no) and noncases by biops

58 d the current clinical parameters of digital rectal examination, prostate-specific antigen, and Gleas

59 constipation criteria, stool diary, digital rectal examination, rectal diameter assessed from transa

60 tate biopsy on the basis of abnormal digital rectal examination results or elevated prostate-specific

61 igen (PSA) level, PSA density, race, digital rectal examination results, and biopsy results before MR

62 e-specific antigen (PSA) or abnormal digital rectal examination results, often with prior negative bi

63 to 0.78 for models without and with digital rectal examination results, respectively (P < .001 for b

64 nsrectal ultrasound (TRUS) findings, digital rectal examination results, serum PSA level, and excess

65 Rectal examination revealed a hard mass in the retrorect

66 A digital rectal examination revealed an enlarged prostate with an

67 state specific antigen, and abnormal digital rectal examination, serum 25-OH D less than 30 ng/mL was

68 um prostate-specific antigen levels, digital rectal examination status, stage, grade, primary treatme

69 A digital rectal examination that is abnormal but not suspicious f

70 rostate-specific antigen testing and digital rectal examination (the latter available for >60% of res

71 n patients who have abnormalities on digital rectal examination, the risk for a large intracapsular t

72 By comparing transrectal US and digital rectal examination, the sensitivities were 76% and 44% (

73 On digital rectal examination, the tumor is palpated approximately

74 ories are prostate specific antigen, digital rectal examination, transrectal biopsy and their repeate

75 elevated PSA levels and/or abnormal digital rectal examination underwent transrectal US-guided sexta

76 cted history, examination (including digital rectal examination), urinalysis and bladder diary as bei

77 eded 4.0 ng per milliliter or if the digital rectal examination was abnormal.

78 Digital rectal examination was often not performed but at least

79 A digital rectal examination was performed and revealed a suspicio

80 Digital rectal examination was performed in only 56.4%.

81 y, while sensitivities of biopsy and digital rectal examination were 48% and 16%, respectively.

82 :ERG (T2:ERG) RNA in the urine after digital rectal examination would improve specificity over measur